Craig Norton

TL;DR: Clinical benefit was associated with loss-of-function mutations in the PBRM1 gene, which encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, and may alter global tumor-cell expression profiles to influence responsiveness to immune checkpoint therapy.

TL;DR: Early decline and NLR at 6 weeks are associated with significantly improved outcomes in mRCC patients treated with ICB, and the prognostic value of the readily-available NLR warrants larger, prospective validation.

TL;DR: Patients with favorable- and intermediate-prognostic criteria disease treated with third-line targeted therapy have an associated longer overall survival compared with those with poor risk disease.

TL;DR: It is shown that patients who benefitted clinically from anti–PD-1/PD-L1 therapy can experience sustained beneficial responses, not needing further therapies after the initial discontinuation of treatment due to irAEs.

TL;DR: targeted next-generation sequencing mutation calls from two independent cohorts support the theory that ccRCC primary tumours and metastases encompass a uniform distribution of common genomic alterations tested by next- generation sequencing targeted panels.